Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

Introduction Clozapine and olanzapine are some of the most effective antipsychotics, but both are associated with weight gain and relevant metabolic disturbances, including pre-diabetes and diabetes. Non-pharmacological/behavioural interventions have had limited effects counteracting these adverse e...

Full description

Bibliographic Details
Main Authors: Jimmi Nielsen, Christoph U Correll, Tina Vilsbøll, Maj Vinberg, Claus Ekstrøm, Anders Fink-Jensen, Heidi Storgaard, Filip K Knop, Ole Mors, Marie Reeberg Sass, Andreas Aalkjær Danielsen, Ole Köhler-Forsberg, Mette Ødegaard Nielsen, Anders Mikael Sjödin
Format: Article
Language:English
Published: BMJ Publishing Group 2023-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/1/e068652.full

Internet

https://bmjopen.bmj.com/content/13/1/e068652.full

Similar Items